



**NH September Formulary Update  
Effective September 6, 2017**

**Angiotensin Converting Enzyme (ACE) Inhibitor  
Therapeutic Interchange Update**

**Effective September 6, 2017, the following formulary ACE Inhibitor update will occur:**  
Formulary: ramipril will become the “go to” ACE Inhibitor for all excluded ACE Inhibitors  
(perindopril remains formulary and enalapril remains formulary restricted to pediatrics).

Excluded: trandolapril will be an excluded ACE Inhibitor  
(benazepril, cilazapril, fosinopril, lisinopril, quinapril remain excluded)

**Table 10: Angiotensin Converting Enzyme (ACE) Inhibitors:**

ACE Inhibitor Equivalent Doses	
Drug	Dose*#
benazepril (Lotensin)	10 mg
captopril (Capoten)	No substitution
cilazapril (Inhibace)	2.5 mg
enalapril maleate (Vasotec)	5 mg
enalapril sodium	4 mg
fosinopril (Monopril)	10 mg
lisinopril (Prinivil, Zestril)	10 mg
perindopril (Coversyl)	No substitution
quinAPRIL (Accupril)	10 mg
trandolapril (Mavik)	1 mg
ramipril (Altace)	2.5 mg

\*The dose of the excluded ACE Inhibitor order will be used to calculate an equivalent ramipril dose

# BID orders are automatically substituted with the equivalent ramipril dose and also given BID

Pediatric patients are exempt from this interchange. Enalapril is Restricted to pediatric patients.

**September 6, 2017**  
**For the information of  
physicians, nurses and  
pharmacists**  
**PLEASE POST**

Best Practice	
Drug Discontinuation	
Medication Change	
Drug Shortage	
Formulary changes	✓

**For further information contact:**  
**Nancy Dyck or Gordon Harper**  
**Medication Use Management**  
**Pharmacists**  
**mumpharmacist@northernhealth.ca**